Editor's Choice: NASH is becoming the leading cause of chronic liver disease in US & other Western countries. Lai et al report that the SGLT2 inhibitor empagliflozin effectively reversed liver histologic changes, holding promise for NASH treatment. h
Fatty liver emerging as #1 cause of liver disease globally. US FDA hasn't approved drugs for this indication but SGLT2 inhibitors have shown promise. Chan et al report histologic remission in patients with alcoholic steatohepatitis after drug treatment.
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @CarlosGR82: los iSGLT2 empiezan a posicionarse como tratamiento en pacientes con EHNA. Estaría bien un head to head con pioglitazona. N…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @CarlosGR82: los iSGLT2 empiezan a posicionarse como tratamiento en pacientes con EHNA. Estaría bien un head to head con pioglitazona. N…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @CarlosGR82: los iSGLT2 empiezan a posicionarse como tratamiento en pacientes con EHNA. Estaría bien un head to head con pioglitazona. N…
RT @CarlosGR82: los iSGLT2 empiezan a posicionarse como tratamiento en pacientes con EHNA. Estaría bien un head to head con pioglitazona. N…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @CarlosGR82: los iSGLT2 empiezan a posicionarse como tratamiento en pacientes con EHNA. Estaría bien un head to head con pioglitazona. N…
los iSGLT2 empiezan a posicionarse como tratamiento en pacientes con EHNA. Estaría bien un head to head con pioglitazona. NO OLVIDEMOS que el principal tratamiento es una correcta alimentación!!!!
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
Seguimos acumulando beneficios de esta familia de Antidiabéticos.
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @drshafikuchay: A pilot biopsy study, showing empagliflozin not only reduces liver fat, but also reduces inflammation and improves fibro…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
Interesting findings (biopsy-based), but the comparison with the “historical placebo control” sounds strange. #NAFLD #NASH #diabetESP
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
RT @moreno_perez_o: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary hist…
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with T2D. A pilot study, with primary histological evidence that empagliflozin may be useful in NASH @diabeteSEEN @sociedadSEEN @SEDiabetes @aegastro @SEMERGENap @semfyc https://t
A pilot biopsy study, showing empagliflozin not only reduces liver fat, but also reduces inflammation and improves fibrosis..@DanielJDrucker #nash https://t.co/Fd6nqD3uUY